Aligos Therapeutics (ALGS) Net Income towards Common Stockholders (2019 - 2026)
Aligos Therapeutics (ALGS) posted Net Income towards Common Stockholders of -$1.5 million for Q2 2026, compared with -$15.86 million a year earlier.
Powered by 
Analysis
Aligos Therapeutics (ALGS) Net Income towards Common Stockholders (2019 - 2026) Analysis & Trends
For the trailing twelve months through Jun 30, 2026, Net Income towards Common Stockholders at Aligos Therapeutics was -$75.96 million; for FY2025, it was -$24.19 million.
- In prior years, Aligos Therapeutics' Net Income towards Common Stockholders was -$131.21 million in FY2024, -$87.68 million in FY2023, -$96.05 million in FY2022 and -$128.33 million in FY2021.
- The Q2 2026 figure stands as the highest quarterly Net Income towards Common Stockholders since Q1 2025.
- According to Business Quant data, Net Income towards Common Stockholders for the three prior quarters was -$23.04 million (Q1 2026), -$19.88 million (Q4 2025) and -$31.54 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,129.53 Bn | 1,098.12 Bn | 19.71 Bn | 7.10 Bn |
| 2 | Johnson & Johnson | 635.66 Bn | 555.53 Bn | 17.30 Bn | 210.00 Mn |
| 3 | AbbVie | 504.81 Bn | 477.92 Bn | 12.70 Bn | 3.61 Bn |
| 4 | Merck | 358.21 Bn | 312.59 Bn | 12.21 Bn | -1.34 Bn |
| 5 | Novartis Ag | 290.21 Bn | 254.20 Bn | 11.24 Bn | 3.26 Bn |
| 6 | Astrazeneca | 264.86 Bn | 238.55 Bn | 12.86 Bn | 2.51 Bn |
| 7 | Amgen | 237.58 Bn | 192.98 Bn | 7.24 Bn | 2.38 Bn |
| 8 | Gilead Sciences | 194.88 Bn | 169.08 Bn | 6.22 Bn | -10.50 Bn |
| 9 | Pfizer | 171.14 Bn | 117.79 Bn | 10.94 Bn | -248.00 Mn |
| 10 | Aligos Therapeutics | 50.43 Mn | -277.97 Mn | - | -1.50 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.50 Mn |
| Mar 31, 2026 | -23.04 Mn |
| Dec 31, 2025 | -19.88 Mn |
| Sep 30, 2025 | -31.54 Mn |
| Jun 30, 2025 | -15.86 Mn |
| Mar 31, 2025 | 43.09 Mn |
| Dec 31, 2024 | -82.15 Mn |
| Sep 30, 2024 | -19.26 Mn |
| Jun 30, 2024 | 5.06 Mn |
| Mar 31, 2024 | -34.86 Mn |
| Dec 31, 2023 | -27.89 Mn |
| Sep 30, 2023 | -18.04 Mn |
| Jun 30, 2023 | -18.79 Mn |
| Mar 31, 2023 | -22.96 Mn |
| Dec 31, 2022 | -21.89 Mn |
| Sep 30, 2022 | -18.62 Mn |
| Jun 30, 2022 | -19.92 Mn |
| Mar 31, 2022 | -35.62 Mn |
| Dec 31, 2021 | -37.71 Mn |
| Sep 30, 2021 | -33.12 Mn |
API Access
Aligos Therapeutics Net Income towards Common Stockholders API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=ALGS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "net-income-towards-common-stockholders", "ticker": "ALGS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=ALGS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();